[ 1 ] Bohan A, Peter JB. Polumyositis and dermatomyositis[J]. N Engl J Med, 1975, 292: 344-347.
[2]
[ 2 ] 蒋明. 中华风湿病学[M]. 北京: 华夏出版社, 2004: 1192.
[3]
[ 3 ] Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases[J]. Clin Rheumatol, 2011, 30(12): 1595-1601.
[4]
[ 4 ] Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis[J]. Curr Rheumatol Rep, 2012, 14(3): 275-285.
[5]
[ 5 ] Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy[J]. Curr Rheumatol Rep, 2002, 4(5): 415-426.
[ 7 ] Woo JH, Kim YJ, Kim JJ, et al. Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease[J]. Mod Rheumatol, 2013, 23(3): 503-508.
[8]
[ 8 ] Murakami Y, Kanazawa K, Okuno K, et al. High-grade neuroendocrine carcinoma of the lung presenting an unusual spread mimicking pleural mesothelioma associated with dermatomyositis[J]. Am J Med Sci, 2004, 327(4): 227-230.
[9]
[ 9 ] Chen YJ, Wu CY, Huang YL, et al. Cancers risks of dermatommyositis and polyostis: a nationwide cohort study in Taiwan[J]. Arthritis Res Ther, 2010, 12(2): 70.
Ungprasert P, Leeaphorn N, Hosiriluck N, et al. Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in Asian population[J/OL]. ISRN Rheumatol, 2013. http://dx.doi.org/10.1155/2013/509354.
[12]
Meyer O, Hayem G, Palazzo E, et al. Interstitial lung disease due to polymyositis or dermatomyositis:effect of a 6-month course of i.v.pulse cyclophosphamide[J]. Clin Exp Rheumatol, 2005, 23(5): 724.
Chen IJ, Tsai WP, Wu YJ, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases[J]. Rheumatology (Oxford), 2010, 49(12): 2429-2437.
[15]
Gupta R, Wayangankar SA, Targoff IN, et al. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review[J]. Int J Cardiol, 2011, 148(3): 261-270.